A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents.

J Clin Med · 2018 · PMC5852445 · PMID 29439477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The ANNEXA-R trial [ 120 ] specifically investigated the reversal of rivaroxaban in healthy volunteers and showed that there was a 92% reduction of anti-factor Xa activity compared to baseline, which was highly significant compared to placebo.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.